New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade
Alex Brill and Christy Robinson look at the US biosimilars market a decade after the first biosimilar approval.
Implications of Cannabis Legalization for the US Federal Budget
While the details of future federal legislation and executive actions to legalize, regulate, and tax cannabis remain unknown, such policies could have significant impacts on the federal budget.
A Balanced Plan for Fiscal Stability and Economic Growth
Our plan seeks to achieve long-term fiscal stability and promote economic growth by aligning federal spending and revenue and pursuing market-based policy reforms.
Despite Headwinds, Biosimilars Market Is Growing in 2024
The Food and Drug Administration (FDA) has approved a record number of biosimilars in 2024, and the year is only half over.
IRS says it will deny most claims of pandemic tax credit for employers
“A big responsibility is falling on the IRS to deal with this problem, when, in fact, Congress could be dealing with this problem,” Brill said.”
- FDA Continues to Expedite Biosimilar Development
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
- MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
- The Unsung Hero of the OBBBA: Permanent Expensing
- Alex Brill Interviewed by Biosimilars Review & Report
- MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
